9 completed. 6 Not applicable, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 6 | Completed 6 |
| Early Phase 1 | 1 | Completed 1 |
Follow AB Biotek: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Safety and Tolerability of Three Doses of Diamine Oxidase (DAO) in Healthy Volunteers Dose 1 (42mg) of DAO, Placebo, Dose 2 (84mg) of DAO - Safety and Tolerability in Healthy Volunteers | Not applicable | Completed | AB Biotek | 43 | 2024-07-08 | 2025-05-30 |
| Evaluation Of The Diamine Oxidase Supplementation Effect In Patients With Insomnia Symptoms DAO supplement, Placebo - Insomnia, Insomnia Type; Sleep Disorder | Not applicable | Completed | AB Biotek | 108 | 2024-03-13 | 2025-06-19 |
| Kinetic Study Of Supplementation With The Enzyme Diamine Oxidase In Patients With Histamine Intolerance Diamino Oxidase - Histamine Intolerance | Not applicable | Completed | AB Biotek | 15 | 2023-06-23 | 2025-06-18 |
| DAO DEFICIENCY SCREENING AMONG PATIENTS WITH INSOMNIA SYMPTOMS Insomnia, Insomnia Disorder | Completed | AB Biotek | 200 | 2023-05-05 | 2025-05-30 | |
| Efficacy and Tolerability of ABB I5 Prebiotic and ABB C22 Postbiotics for the Management of Constipation and Gastrointestinal Well-being: a Pilot Trial ABB i5, ABB C24 - Constipation | Early Phase 1 | Completed | AB Biotek | 34 | 2023-04-25 | 2024-12-17 |
| Prevalence of DAO (diamino Oxidase) Deficiency in Newborns DAO Genetic Variants | Completed | AB Biotek | 200 | 2023-02-28 | 2024-11-29 | |
| Medical Nutrition Formulations Enriched With Postbiotics for the Management of Gastrointestinal Disorders ABB S3, ABB C22, Placebo - Diarrhoea of Diverse Aetiology Requiring Oral Rehydration Therapy, Diarrhoea and Gastrointestinal Symptoms Secondary to Enteral Nutrition | Not applicable | Completed | AB Biotek | 100 | 2023-01-27 | 2025-10-07 |
| Fibromyalgia Treatment With Enzyme DAO fibroDAO®, Placebo - Fibromyalgia | Not applicable | Completed | Centros de Investigación de Nutrición y Salud | 100 | 2022-02-22 | 2023-03-23 |
| Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine ABBC1 Immunoessential, Placebo - Immunity, Vaccine Reaction | Not applicable | Completed | AB Biotek | 72 | 2020-10-29 | 2022-07-21 |
Sleep Initiation and Maintenance Disorders (2) · COVID-19 (1) · Constipation (1) · Cytokine Release Syndrome (1) · Diarrhea (1) · Fibromyalgia (1) · Immunologic Deficiency Syndromes (1) · Influenza, Human (1) · Sleep Wake Disorders (1)
Spain (8) · South Sudan (1)
Ismael San Mauro Martin, PhD (1) · Julia Ferrer Garcia, MSc (1) · Karol Enrique Uscamaita Amaut, MD (1) · Pol Molina, PharmaD (1)
PMID 16213065, PMID 17344507, PMID 17921398, PMID 18550812, PMID 19275682, PMID 21445287, PMID 22381456, PMID 25278144, PMID 26031679, PMID 26817502, PMID 27103044, PMID 30935016, PMID 31544248, PMID 32223047, PMID 32361099, PMID 33072682, PMID 33301246, PMID 33597143, PMID 36979637, PMID 39200725, PMID 40126284, PMID 40780410, PMID 41437955, PMID 8375567